NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Inclusion Criteria

• •1. Men or women≥18 years old,
• •2. Patient with NKG2DL+ cell tumors confirmed by pathology and histology，
• •3. Fail or unwilling to receive first-line treatment,
• •4. Disease must be measurable according to the corresponding guidelines,
• •5. Main organs function normally and meet following requirements:
• •Routine blood index（No Blood transfusion within 14 days） 1)HB≥90g/L; 2)ANC≥1.5×109/L; 3)PLT≥75×109/L； Serum biochemicals index 1) BIL \<1.5 upper normal limit (ULN); 2) ALT and AST\<2.5×ULN; In the case of liver metastasis, ALT and AST\<5×ULN; 3) Serum Cr≤1×ULN, endogenous creatinine clearance≥50ml/min (Cockcroft-Gault formula); 4) ECOG physical condition score: 0-2
• •6. Expected survival time ≥3 months,
• •7. Patient with adequate bone marrow reserve, hepatic and renal functions,
• •8. No other uncontrolled diseases such as lung, kidney and liver infection before enrollment,
• •9. Women of child-bearing age must undergo a negative pregnancy test (serum or urine) within 7 days prior to enrollment and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last dose; men should agree to contraception during the observation period and within 8 weeks of the last dose,
• •10. Patients voluntarily participated in this trial and sign the informed consent form,
• •11. Patients with compliance and expected to follow up the efficacy and adverse reactions as required by the protocol.